ArticleJournal of contemporary brachytherapy2026
Hybrid adjuvant therapy with 3D-printed orbital brachytherapy and stereotactic body radiotherapy for recurrent adenoid cystic carcinoma: A technical note.
Article in Journal of contemporary brachytherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Recurrent head and neck cancers, involving paranasal sinus and skull base in previously irradiated patients, present significant challenges due to proximity of critical organs. We evaluated the feasibility and safety of a hybrid approach combining 3D-printed interstitial brachytherapy (ISBT) and stereotactic body radiotherapy (SBRT) for re-irradiation. Material and methods: A 39-year-old male with a history of adenoid cystic carcinoma (ACC) of the right petrous apex and Meckel's cave, initially treated with sub-total resection and 66 Gy radiotherapy in 2017, presented six years later with recurrence in the right nasal cavity extending to the medial orbital wall. Following endoscopic debulking, a residual lesion (1.8 cm × 1.6 cm × 1.2 cm) remained. A hybrid re-irradiation strategy was employed, consisting of template-guided ISBT (8 Gy in 2 fractions) using a customized 3D-printed orbital applicator, followed by volumetric modulated arc therapy (VMAT)-based SBRT (40 Gy in 10 fractions). Results: The hybrid course delivered a cumulative physical dose of 41.82 Gy (ISBT D Conclusions: This case demonstrates the feasibility and safety of hybrid ISBT-SBRT approach for recurrent orbital ACC. In anatomically complex sites, this strategy allows optimal target coverage while respecting organ at risk (OAR) constraints.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.